Clinical trial
Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men…
NCT04396808 · University of Michigan Rogel Cancer Center, Other · Recruiting
Key facts
| NCT number | NCT04396808 |
|---|---|
| Title | Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer |
| Official title | Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR): A Randomized Multi-center Study for Men With Newly Diagnosed Favorable Risk Prostate Cancer |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Collaborators | National Institutes of Health (NIH) NIH Myrexis Inc. Industry Veracyte, Inc. MDx Health |
| Status | Recruiting |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Device, Other |
| Interventions | Decipher, Prolaris, Oncotype Dx Genomic Prostate Score (GPS), Standard of care (askMUSIC score) |
| Enrollment | 900 |
| Start date | Nov 5, 2020 |
| Primary completion | Apr 30, 2028 |
| Completion | Apr 30, 2031 |
| First posted | May 21, 2020 |
| Last update posted | Jan 7, 2026 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: